Operating revenue for the fourth quarter stood at Rs 4,517 crore, up 10% YoY, after adjusting for one-time generic Lenalidomide sales in Q4FY25. EBITDA for Q4 was at Rs 1,073 crore, adjusted for generic lenalidomide sales, up 29% YoY, with a margin of 23%.
The Board of Directors of the company has recommended a final dividend of Re. 0.50 per share at the rate of 10% of the face value of the share, for the financial year ending March 31, 2026.
Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said that the company closed FY26 on a strong note despite a complex geopolitical environment.
“This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration,” she said.
Live Events
“We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint,” Shaw added.
Going ahead, the focus will be on profitability enhancement and long-term value creation, she said.For the full year FY26, the company reported operating revenue at Rs 16,927 crore, up 13% YoY, after adjusting for onetime generic Lenalidomide sales in FY25.
Shreehas Tambe, CEO & Managing Director, Biocon, said: “FY26 was a pivotal year for Biocon, marked by the successful integration of our biosimilars and generics business to create one unified biopharmaceutical enterprise with greater scale, capability, and reach. Even as we integrated the businesses, Biocon delivered 200 basis points of EBITDA margin expansion at a consolidated level on a like-to-like basis, driven by an improved product mix and operational excellence.”
Growth was led by strong performance in advanced markets and key tender wins across emerging markets.